| Document |
Document Title |
|
WO/1995/005178A1 |
The present invention relates to cyclopentane heptanoic or cyclopentane heptenoic acid, 2-hydrocarbyl sulfonamidomethyl, and derivatives thereof, useful as therapeutic agents. In particular, the therapeutic agents of this invention are u...
|
|
WO/1994/027962A1 |
To provide a novel PGE1 analog having cytoprotective and gastric secretoinhibitory effects superior to those of the conventional PGE1 analogs and being excellent in the persistence of drug effect and reduced in side effects. A prostaglan...
|
|
WO/1994/019319A1 |
A process for producing an intermediate for a 13,14-didehydroprostaglandin E, represented by general formula (I), (wherein R6 represents -COOR9, cyano, hydroxy, -OCOR10 or -CONR11R12; A represents vinylene, ethynylene, phenylene -C = C =...
|
|
WO/1994/010141A1 |
The present invention relates to cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or arylaliphatic derivatives. In particular, heptenylnitrate and heptanylnitrate 2-aliphatic or arylaliphatic derivatives, substituted at the 3 and...
|
|
WO/1994/009788A1 |
The present invention relates to cyclopentane heptenylsulfinylalkyl and heptanylsulfinylalkyl-2-aliphatic or arylaliphatic derivatives. In particular, heptenylsulfinylmethyl and heptanylsulfinylmethyl 2-aliphatic or arylaliphatic derivat...
|
|
WO/1994/008959A1 |
A prostaglandine derivative represented by general formula (I), wherein R1 represents hydrogen or C1-C6 alkyl, and R2 represents cyclohexyl or cyclopentylmethyl. It has various physiological activities including the inhibition of platele...
|
|
WO/1994/008586A2 |
The present invention provides novel 2-aliphatic or arylaliphatic cyclopentane heptanoic and heptenoic acid derivatives including at least one azido substituent. In particular 2-aliphatic or arylaliphatic cyclopentane heptenyloic and cyc...
|
|
WO/1994/008587A1 |
Compounds of formula (1) where the dotted line represents a bond or the absence of a bond, the wavy lines represent bonds which are either in cis or trans configuration; R1 represents H, or CO-R2 where R2 is lower alkyl of 1 to 6 carbons...
|
|
WO/1994/008960A1 |
A prostaglandin E1 analog represented by formula (I), wherein A represents vinylene or ethinylene; and R1 represents hydrogen, C1-C8 alkyl or C3-C8 cycloalkyl. This compound has a selective, persistent and potent antiulcerative effect an...
|
|
WO/1994/008961A1 |
A prostaglandin E1 analog represented by formula (I), wherein R1 represents hydrogen or C1-C6 alkyl; and X represents oxygen and R2 represents (a) or (b); or alternatively, X represents sulfur and R2 represents (c). This compound has a p...
|
|
WO/1994/007838A1 |
An isocarbacyclin with the alpha-chain modified with phenylene, cycloalkylene or thiophenediyl. It has the activity of inhibiting DNA synthesis of human smooth muscle cells and is expected to inhibit vascular hypertrophy.
|
|
WO/1994/007884A1 |
The invention aims at providing a safe technique for remarkably improving the yield of an alpha,beta-unsaturated ketone through introduction of an omega-chain into an aldehyde without being accompanied by the generation of hydrogen in th...
|
|
WO/1994/006291A1 |
Methods, compositions and devices for synthesizing combinatorial libraries of various useful compounds, such as benzodiazepines, prostaglandins, beta-turn mimetics and glycerol derived drugs is described. Methodologies for solid phase sy...
|
|
WO/1994/006750A1 |
This invention relates to a prostaglandin-bisphosphonate compound of formula (I) and its pharmaceutically acceptable salts. The claimed compounds are effective as delivery agents of prostaglandins to treat osteoporosis and related bone d...
|
|
WO/1994/006433A1 |
The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives, substituted in the 1-position with halo, methyl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, ether or thioether groups, e.g...
|
|
WO/1994/005619A1 |
An optically active compound represented by general formula (I), a mixture thereof, and a carcinostatic and osteogenesis promoter each containing the same as the active ingredient, wherein Y represents hydrogen or halogen; A represents h...
|
|
WO/1994/005631A1 |
The invention concerns 9-chloroprostaglandin esters and amides of general formula (I), methods of preparing them and their use as drugs.
|
|
WO/1994/002457A1 |
To provide a novel PG derivative with an excellent platelet aggregation inhibitor effect. A prostaglandin derivative represented by general formula (I) and a salt thereof.
|
|
WO/1993/026053A1 |
A thermoelectric sensor element that is adapted to respond to thermal radiation is capable of manufacture into a sensor array on a single crystal semiconductor means, such as silicon. An anisotropically etched pit is provided under the s...
|
|
WO/1993/016041A1 |
To produce a prostaglandin E in a short time and in a high yield while minimizing the formation of isomers. A process for producing a prostaglandin E represented by general formula (I) wherein A represents an arbitrary group not particip...
|
|
WO/1993/014743A2 |
The present invention provides a method of treating ocular hypertension which comprises applying to the eye an amount sufficient to treat ocular hypertension of a compound of formula (I), wherein the wavy line attachments indicate either...
|
|
WO/1993/013062A1 |
The present invention relates to a novel class of halogenated tetraenyl prostaglandin compounds represented by general formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is -CH=CH- or -CH2-CH2-; R1 is H or a lower alkyl...
|
|
WO/1993/011105A1 |
Leukotriene-B¿4? derivatives have the formula (I), in which R?1¿ stands for CH¿2?OH, CH¿3?, CF¿3?, COOR?5¿, CONR?6¿R?7¿, or R?1¿ represents together with R?2¿ a carbonyl group; R?2¿ and R?3¿ are different or the same and stan...
|
|
WO/1993/007876A1 |
A remedy for hepatic diseases, containing beraprost or a pharmacologically acceptable salt thereof as the active ingredient, which has an excellent activity of treating various hepatic diseases and is safe, chemically stable and orally a...
|
|
WO/1993/007118A1 |
The invention concerns 9-substituted bicylo[3.3.0]octane derivaties of formula (I) and their physiologically acceptable bases, and also the $g(a)-, $g(b)- or $g(g)-cyclodextrin clathrates, and the compounds of formula (I) encapsulated in...
|
|
WO/1993/001816A1 |
The invention is related to the field of treating gastric and duodenal disorders and more specifically to the use of certain 13,14-dihydro-prostaglandin E derivatives, especially of PGE2, which are modified to contain a ring structure in...
|
|
WO/1993/000329A1 |
The invention relates to a novel process for the preparation of 13,14-dihydro-15(R)-17-phenyl-18,19,20-trinor-PGF2alpha isopropyl ester of formula (I), wherein R stands for saturated or unsaturated straight, branched or cyclic C1-7 alkyl...
|
|
WO/1992/022334A1 |
This invention provides novel compounds used in a method of determining platelet deposition. These compounds include 123I-SAP and analogues. Also provided is a method of determining platelet deposition in a subject comprising binding an ...
|
|
WO/1992/020648A1 |
The present invention relates to 2-decarboxyl-2-acylthioalkyl prostaglandins that are potent ocular hypotentives, and are particularly suitable for the management of glaucoma.
|
|
WO/1992/018472A1 |
Object: to provide a novel prostaglandin E�1? which is excellent in drug efficacy while reduced in adverse reactions as compared with conventional ones. Constitution: a PGE�1? analogue represented by general formula (I) and its salt,...
|
|
WO/1992/018473A1 |
Object: to provide a novel prostaglandin E�1? which is excellent in drug efficacy and prolonged action while reduced in adverse reactions as compared with conventional ones. Constitution: a PGE�1? analogue represented by general form...
|
|
WO/1992/016504A1 |
The invention discloses new leukotriene B4 derivatives of formula (I), wherein R?1� stands for CH�2?OH, CH�3?, CF�3?, COOR?5�, CONR?6�R?7�, or R?1� together with R?2� stands for a carbonyl group, R?2� and R?3� are t...
|
|
WO/1992/013836A1 |
The present invention relates to novel 2-decarboxyl-2-hydroxyalkyl derivatives of 5-trans prostaglandins of the F series. The invention further concerns pharmaceutical compositions and methods for reducing or maintaining intraocular pres...
|
|
WO/1992/010193A2 |
The invention relates to homo-prostaglandin derivatives. More particularly, the present invention concerns 1a-homo derivatives of naturally occurring and synthetic prostaglandins, the corresponding bis- and trishomo-prostaglandin compoun...
|
|
WO/1992/010473A2 |
The present invention relates to 2-decarboxyl-2-alkoxyalkyl prostaglandins that are potent ocular hypotentives, and are particularly suitable for the management of glaucoma.
|
|
WO/1992/009573A2 |
The invention concerns cyclopentane ether derivatives of formula (I), their salts with physiologically tolerable bases, as well as the $g(a), $g(b)- and $g(g)-cyclodextrin clathrates and compounds of formula (I) encapsulated with liposom...
|
|
WO/1992/008697A2 |
The invention relates to 9-halogen-11$g(b)-hydroxy prostaglandin derivatives of formula (I) in which Z is the radical (a) or (b), Hal is an $g(a) or $g(b)-fixed chlorine or fluorine atom, R?1¿ is the radical CH¿2?OH or (c), R?2¿ is a ...
|
|
WO/1992/008465A2 |
The present invention concerns 2-decarboxyl-2-aminoalkyl derivatives of naturally occurring and synthetic prostaglandins, N-substituted derivatives, ester prodrugs and homologues of such compounds that are potent ocular hypotensives, and...
|
|
WO/1992/004312A1 |
The invention relates to a process for making E/Z mixtures of 2-(6-alkyl-bicyclo-[3.3.0]-octane-3-ylidene)-acetic acid esters of formula (I) in which the E proportion is predominant.
|
|
WO/1992/002495A1 |
The invention relates to cyclopentane derivatives of formula (I) and their salts with physiologically tolerables bases and the $g(a), $g(b) or $g(g)-cyclodextrin clathrates and the liposome-encapsulated compounds of formula (I), a proces...
|
|
WO/1992/002496A1 |
Method for preparing 13,14-dihydro-17-phenyl analogues of PGF2alpha or PGE2 comprising the step of hydrogenating the double bond in an intermediate compound (I) without deoxygenation of the allylic alcohol to give one of the intermediate...
|
|
WO/1992/002494A1 |
The invention relates to cyclopentane derivatives of formula (I) in which there is a double bond between the carbon atoms of centres a-b or b-c, and their salts with physiologically tolerable bases, and $g(a), $g(b) or $g(g)-cyclodextrin...
|
|
WO/1991/015493A1 |
Higher order cuprate complexes are prepared by means of a transmetalation from a corresponding zirconate intermediate. This process is particularly valuable with respect to the preparation of vinylic side chains such as are present in pr...
|
|
WO/1991/014675A1 |
The invention relates to bicyclo[3.3.0]octane derivatives of formula (I), and their enantioners. In formula (I) not more than one double bond is located between the carbon atoms of the centres a-b or b-c or b-d, and R?1� is (a'), (b'),...
|
|
WO/1991/013869A1 |
A 15-deoxyprostaglandin derivative of general formula (I) and an intraocular pressure depressant containing said derivative or a pharmaceutically acceptable salt thereof as the active ingredient . In formula (I), (a) is a five-membered r...
|
|
WO/1991/009012A1 |
A process for the preparation of a prostaglandin of formula (I), wherein n is 1, 2, 3 or 4, R1 and R2, independently of each other, are alkyl, OH, alkoxy, ketone, halogen, hydrogen, nitro, amino or ether, R3 is hydrogen, alkyl, haloalkyl...
|
|
WO/1991/005766A1 |
A 2-substituted 2-cyclopentenone of formula (I) and a carcinostatic agent and an osteogenesis promoter containing the same as the active ingredient.
|
|
WO/1991/001303A1 |
$g(D)?8�- and $g(D)?9�-prostaglandine derivates are disclosed, having the formula (I), in which (a) represents the residues (b) or (c); R?1� represents the groups (d), (e), COOR?4� or CONHR?5�; R?2� and R?3� represent each ...
|
|
WO/1991/001302A1 |
9-fluor-postaglandine derivates are disclosed, having the formula (I), in which R?1� represents the groups (a), (b), COOR?4� or CONHR?5�; R?2� and R?3� represent each a hydrogen atom or a free or functionally transformed hydrox...
|
|
WO/1990/014329A1 |
Compounds of formula (I) in which the residues have the following meanings: a is (II) or (III); R?1¿ is CH¿2?OH, CH¿3?, CF¿3?, COOR?5¿ with R?5¿ or, A is a trans, trans-CH=CH-CH=CH- or tetramethylene group; B is an alkylene group w...
|
